Table 1.
Relationship among livin, survivin, caspase-3 expressions and clinicopathological features [n (%)]
| n | Livin | P | Survivin | P | Caspase-3 | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||
| Positive | Negative | Positive | Negative | Positive | Negative | |||||
| PSA | ||||||||||
| < 4 ng/mL | 8 (18.60) | 8 (100.00) | 0 (0.00) | 0.536 | 7 (87.50) | 1 (12.50) | 0.477 | 1 (12.50) | 7 (87.50) | 0.317 |
| 4~10 ng/mL | 16 (37.21) | 14 (87.50) | 2 (12.50) | 12 (75.00) | 4 (25.00) | 5 (31.25) | 11 (68.75) | |||
| > 10 ng/mL | 19 (44.19) | 18 (94.74) | 1 (5.26) | 17 (89.47) | 2 (10.53) | 4 (21.05) | 15 (78.95) | |||
| Clinical staging | ||||||||||
| I+II | 19 (44.19) | 18 (94.74) | 1 (2.33) | 1.000 | 15 (78.95) | 4 (21.05) | 0.451 | 7 (36.84) | 12 (63.16) | 0.027 |
| III+IV | 24 (55.81) | 22 (91.67) | 2 (8.33) | 21 (87.50) | 3 (12.50) | 3 (12.5) | 21 (87.50) | |||
| Pathological grading | ||||||||||
| G1 (2~4) | 4 (9.30) | 4 (100.00) | 0 (0.00) | 0.001 | 4 (100.00) | 0 (0.00) | 0.001 | 0 (0.00) | 4 (100.00) | 0.001 |
| G2 (5~6) | 10 (23.26) | 9 (90.00) | 1 (10.00) | 9 (90.00) | 1 (10.00) | 4 (40.00) | 6 (60.00) | |||
| G3 (7~10) | 29 (67.44) | 27 (93.10) | 2 (6.90) | 23 (79.31) | 6 (20.69) | 6 (20.69) | 23 (79.31) | |||
| Distant metastasis | ||||||||||
| Yes | 13 (30.23) | 13 (100.00) | 0 (0.00) | 0.237 | 11 (84.62) | 2 (15.38) | 0.917 | 3 (23.08) | 10 (76.92) | 0.985 |
| No | 30 (69.77) | 27 (90.00) | 3 (10.00) | 25 (83.33) | 5 (16.67) | 7 (23.33) | 23 (76.67) | |||